Dr. Schmid on Next Steps for the RACE IT Trial in Urothelial Carcinoma

Sebastian C. Schmid, MD, oncologist, Rechts der Isar Medical Center, Technical University of Munich, Germany, discusses the future of the phase 2 RACE IT trial (NCT03529890) in urothelial carcinoma.

RACE IT evaluated preoperative radiation therapy plus nivolumab (Opdivo) prior to radical cystectomy in patients with locally advanced urothelial carcinoma.

With updated findings from the phase 2 trial, it will be important to examine data on quality of life for enrolled patients, Schmid says. Additional planned research will deliver more detailed data on adverse effects, Schmid adds.

Furthermore, translational projects will explore possible predictive markers for radiation therapy. There are several ways that RACE IT could provide additional valuable data, Schmid concludes.